Related references
Note: Only part of the references are listed.Dkk1 exacerbates doxorubicin-induced cardiotoxicity by inhibiting the Wnt/β-catenin signaling pathway
Liying Liang et al.
JOURNAL OF CELL SCIENCE (2019)
Resistin induces breast cancer cells epithelial to mesenchymal transition (EMT) and sternness through both adenylyl cyclase-associated protein 1 (CAP1)-dependent and CAP1-independent mechanisms
Dimiter Avtanski et al.
CYTOKINE (2019)
Doxorubicin Promotes Migration and Invasion of Breast Cancer Cells through the Upregulation of the RhoA/MLC Pathway
Chien-Liang Liu et al.
JOURNAL OF BREAST CANCER (2019)
Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins
Carrie J. Lovitt et al.
BMC CANCER (2018)
HER2 Overexpression Triggers an IL1α Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance
Shou Liu et al.
CANCER RESEARCH (2018)
Is the pharmaceutical industry's preoccupation with the monotherapy drug model stifling the development of effective new drug therapies?
Ian Edwin Cock
INFLAMMOPHARMACOLOGY (2018)
Investigation of Mitochondrial Metabolic Response to Doxorubicin in Prostate Cancer Cells: An NADH, FAD and Tryptophan FLIM Assay
Shagufta Rehman Alam et al.
SCIENTIFIC REPORTS (2017)
F-actin reorganization by V-ATPase inhibition in prostate cancer
Yamhilette Licon-Munoz et al.
BIOLOGY OPEN (2017)
AMPK activity regulates trafficking of mitochondria to the leading edge during cell migration and matrix invasion
Brian Cunniff et al.
MOLECULAR BIOLOGY OF THE CELL (2016)
Preparation of Photocrosslinked Fish Elastin Polypeptide/Microfibrillated Cellulose Composite Gels with Elastic Properties for Biomaterial Applications
Shinya Yano et al.
MARINE DRUGS (2015)
Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion
Dayana B. Rivadeneira et al.
SCIENCE SIGNALING (2015)
Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion
Dayana B. Rivadeneira et al.
SCIENCE SIGNALING (2015)
Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: Implications for diagnostic microdosing
Gregory T. Wurz et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Inflammatory breast cancer: New factors contribute to disease etiology: A review
Mona M. Mohamed et al.
JOURNAL OF ADVANCED RESEARCH (2014)
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Oktay Tacar et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2013)
Differential effects of methoxyamine on doxorubicin cytotoxicity and genotoxicity in MDA-MB-231 human breast cancer cells
Patricia S. Guerreiro et al.
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS (2013)
Mitochondrial dynamics regulates migration and invasion of breast cancer cells
J. Zhao et al.
ONCOGENE (2013)
The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model
Hui Liu et al.
BMC CANCER (2012)
HER2 Overexpression Elicits a Proinflammatory IL-6 Autocrine Signaling Loop That Is Critical for Tumorigenesis
Zachary C. Hartman et al.
CANCER RESEARCH (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Actin Dynamics at the Leading Edge: From Simple Machinery to Complex Networks
Robert H. Insall et al.
DEVELOPMENTAL CELL (2009)
Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
F- and G-Actin Concentrations in Lamellipodia of Moving Cells
Stefan A. Koestler et al.
PLOS ONE (2009)
Actin, a Central Player in Cell Shape and Movement
Thomas D. Pollard et al.
SCIENCE (2009)
Inflammatory Breast Cancer
Wendy A. Woodward et al.
SEMINARS IN RADIATION ONCOLOGY (2009)
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
Patrick J. Medina et al.
CLINICAL THERAPEUTICS (2008)
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
Xiaoxian Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells
Dongwei Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Cofilin determines the migration behavior and turning frequency of metastatic cancer cells
Mazen Sidani et al.
JOURNAL OF CELL BIOLOGY (2007)
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer
N. Cabioglu et al.
ANNALS OF ONCOLOGY (2007)
Regulation of the actin cytoskeleton in cancer cell migration and invasion
Hideki Yamaguchi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappa B-mediated increase of intracellular doxorubicin accumulation
Jens van Wijngaarden et al.
EUROPEAN JOURNAL OF CANCER (2007)
Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute
KW Hance et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'
E Charafe-Jaufrret et al.
JOURNAL OF PATHOLOGY (2004)
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phosphorylation of ADF/cofilin abolishes EGF-induced actin nucleation at the leading edge and subsequent lamellipod extension
N Zebda et al.
JOURNAL OF CELL BIOLOGY (2000)
Share Paper
